Show overview
Science TLDR has been publishing since 2024, and across the 2 years since has built a catalogue of 79 episodes. That works out to roughly 20 hours of audio in total. Releases follow a fortnightly cadence.
Episodes typically run ten to twenty minutes — most land between 13 min and 20 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 1 months ago, with 18 episodes already out so far this year. The busiest year was 2025, with 47 episodes published. Published by Raymond Ruff.
From the publisher
Ten-minute paper summaries for scientists and experts.Two episodes a week: Mondays feature the top-scoring paper from a curated weekly digest of T cell engager, bispecific antibody, and protein engineering literature. Fridays cover the top trending paper on PubMed — any field, whatever's catching the research community's attention that week.Hosted by Raymond Ruff, a protein scientist working in translational immunotherapeutics. Audio is generated with NotebookLM; the host prompt aims for measured scientific skepticism rather than hype.Feedback and paper suggestions: [email protected]
Latest Episodes
View all 79 episodesEpisode 77: Trending — People prefer to negotiate with women, even when outcomes are identical and gender is unknown
Episode 76: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Episode 75: Trending — A 5.3-million-year-old deep-sea whale necropolis in the Diamantina Zone
Episode 74: Discovery of TCR-like antibodies to the KRAS G12D neoantigen via in silico-in vitro workflow
Episode 73: Trending — Work from Home and Disability Employment
Episode 72: From free speech advocates to critics: The Trump administration’s new rhetoric promotes support for censorship among Trump voters
Episode 71: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Episode 70: Language Modeling Materializes a World Model of Protein Biology
Episode 69: Novel bispecific T-cell engagers overcoming acquired EGFR resistance
Episode 68: The lived experience of rejection sensitivity in ADHD - A qualitative exploration
Episode 67: Deep peptide recognition profiling decodes TCR specificity and enables disease-associated antigen discovery
Episode 66: The political polarization of health outcomes in the USA
Episode 65: Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager
Episode 64: Climate-driven depopulation and adaptation realities in America’s coastal ground zero
Episode 63: Engineering of acidic pH-responsive anti-CD3 binding antibodies
Episode 62: Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study
Episode 61: Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology
Episode 60: A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
Ep 59A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
https://doi.org/10.1038/s41551-025-01569-4
Ep 58Language models cannot reliably distinguish belief from knowledge and fact
https://doi.org/10.1038/s42256-025-01113-8